Emeline COLOMBA

(Breast) Cancer care shouldn’t be a luxury. We lose lives not just to cancer, but to lack of access, high costs, and trials that exclude too many. Innovation must reach every patient, everywhere! @Nature @curijoey @LoiSher @myESMO @ASCO @BreastCancerNow @tmprowell @uicc nature.com/articles/s4152…

The mechanisms by which ultra-processed foods (UPF) drive obesity, an outstanding review article "the evidence is sufficiently strong to justify immediate public health efforts to reduce UPF consumption." nature.com/articles/s4157…

@dplanchard @alicebernardt @GustaveRoussy La fin d’une ère 😢

Departure of a GIANT of genito-urinary oncology from @GustaveRoussy, Prof. Karim Fizazi... A page is turned for Urology Committee, and the next one will be a challenge to write, but many young talents are there and ready to take over. All the best for Karim's future career ...

🦠 The gut isn’t just digestion, it’s defense. Microbiome = hidden player in cancer care. ➡️ Shapes immunity, response, toxicity, survival. 🧪 Fiber, FMT, even bacteria-based drugs are in the game now. #Cancer #Immunotherapy #Microbiome #Oncology #GutHealth @JAMA_current @OncoAlert doi:10.1001/jama.2025.2191

🧵@Institut_cancer se félicite de l’adoption par l’@AssembleeNat de la proposition de loi portant création du registre national des cancers. Il en assurera le pilotage et la mise en œuvre. Cela représente un bond dans la surveillance épidémiologique des cancers sur le territoire.

Congrats Mayuko!! So proud to have collaborated on this work which has such impact for PC patients from diversity! Contrats @MarlinRegine972 about adressing this question in FWI prostate cancer population!👏🏾👏🏾👏🏾

Pasritamig, a First-in-Class, Bispecific T-Cell Engager Targeting Human Kallikrein 2, in Metastatic Castration-Resistant Prostate Cancer: A Phase I Study ascopubs.org/doi/10.1200/JC… This phase I trial of pasritamig, a novel bispecific T-cell–engaging antibody targeting KLK2 in metastatic castration-resistant #prostateCancer , demonstrated a manageable safety profile with mostly low-grade adverse events and minimal cytokine release syndrome. Showed promising preliminary antitumor activity, including a 42.4% PSA response rate and a median radiographic progression-free survival of 7.85 months, supporting further clinical development. @drmnstein @DebbieRobbrecht @DogerStart @MikeSchweizerMD @EmilianoCalvo_ @meavdongen @DrDariaGaut Ping @OncoAlert 🚨 @Silke_Gillessen @AOmlin @nataliagandur @bavilima

💬 Le parcours FRESH illustre pleinement notre engagement à étendre la médecine de précision pour tous les patients atteints de #cancer en France et à l’international, quels que soient leur lieu de vie et leur situation clinique. ⬇

This is a major story from #ASCO25. Randomized phase 3 trial of time of day of immunotherapy infusion. Randomized to infusion before or after 3pm. Early infusion far superior: PFS 11.3 vs 5.7 HR 0.42, OS HR 0.45! Impactful, pragmatic, not costly. This should be a bigger story.

@DrChoueiri @GustaveRoussy @ASCO @ASCOPost @JCO_ASCO @CapuBaldini contrats !!! Good News for prostate cancer patients!

📢 #ASCO25 | mCRPC Ph. I | KLK2×CD3 bispecific pasritamig: First-in-human (n = 174) shows PSA50 42.4%, median rPFS 6.8 m; G≥3 TRAEs 9.2%, no CRS > G1. by Dr. #CapucineBaldini from @GustaveRoussy et al. Full abstract → [shorturl.at/meFe4] @ASCO @ASCOPost @JCO_ASCO @neerajaiims @montypal @bergsa83 @GlopesMd @VivekSubbiah @OncoAlert @tompowles1 @OncBrothers @medicalwatchBC @yekeduz_emre @CParkMD @Silke_Gillessen @PGrivasMDPhD @TwoOncDocs @OncBrothers @Larvol @nataliagandur @crisbergerot @DrDanielHeng @TiansterZhang @HammersMD @sonpavde @drenriquegrande @scserendipity1 @BraunMDPhD @Uromigos @AminNassarMD @ZiadBakouny @DrRanaMcKay @NazliDizman

#ASCO25 Many new drugs ➡️ welcome but marginal gains. 💰 Cost + ☣️ toxicity Exercise ➡️ marginal cost + negligible toxicity ✅ Evidence based intervention should be added to standard treatment recommendations No need to wait for regulatory approval! Do it now!

Organ preservation dream becoming reality! Neoadjuvant PD-1 blockade led to nonoperative management in 80% of early-stage dMMR solid tumors. 92% recurrence-free survival at 2 years. Surgery was not needed: dignity, function, and hope preserved. @NEJM @gonen_mithat @MSKCancerCenter @OncoAlert @AACR #AACR25 nejm.org/doi/full/10.10…

📰 « J’étais à mille lieues d’imaginer que j’avais un #cancer » : le difficile diagnostic de la maladie chez les adultes jeunes. Retrouvez l'expertise de la Dr Cristina Smolenschi, via le projet Yoda, dans un article de @libe ⤵ liberation.fr/societe/sante/…

Le congrès DICOM est fini @CHUM972 @ArsMartinique RV l’année prochaine le 27 et 28/2/26

Brillante présentation du Pr Rouviere sur l’IA en radiologie dans le cancer de la prostate. @CHUM972 @CHUdeLyon

L’accès au TEP PSMA @CHUM972 nous challenge :chez les patients positifs quel impact sur la stratégie thérapeutique ? 🤩Excellents topo du Pr Fizazi et @CalaisJeremie : un début de réponse 👏🏾

@s_couraud Mais bientôt! Je t’envoie un save the date

Et on remet ça quand pour le poumon ?

Première journée du congrès DICOM @CHUM972 @ArsMartinique : heureux de se retrouver pour échanger sur cancer de la prostate et imagerie

Le dispositif d’appui en personnel de santé propose de consolider l’offre d’oncologie en outre-mer #UCOM ⁦@GRAlumni⁩ #unicancer la1ere.francetvinfo.fr/sante-un-appel…

Lifestyle is a stronger predictor of aging and mortality than genetics. A new Nature study of ~500,000 people found: 🎯 17% of mortality variation was linked to lifestyle (exposome). 🧬 <2% of was explained by genetics. Here’s what you need to know 👇🧵 1/10